NASD · Healthcare · Biotechnology · USA
Corcept Therapeutics Inc is a large cap company (market value between $10 billion and $200 billion) in the Biotechnology industry.
Corcept Therapeutics is a commercial-stage company creating drugs that address cortisol-related disorders across endocrine, cancer, metabolic and neurological conditions. The company sells Korlym and its generic equivalent in the United States for hypercortisolism. It is developing selective cortisol modulators, including relacorilant, for hypercortisolism, solid tumors, amyotrophic lateral sclerosis and metabolic dysfunction-associated steatohepatitis.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Corcept Therapeutics Inc stock.
Overvalued: intrinsic value $11.02 per share, market price $112.10, margin of safety -917.6% (as of 2026-10-19).
Discounting its cash flows at 8.2% (average of 3 methods) values the shares at $11.02; the price of $112.10 is 918% above that value, and 79% of that value comes from beyond year five.
Leak Score: 44/100 on 11 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
112 more in this industry show a wider margin of safety.
CORT is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 8.2% (average of 3 methods) values the shares at $11.02; the price of $112.10 is 918% above that value, and 79% of that value comes from beyond year five.
$11.02 per share (as of the 2026-10-19 close), against a market price of $112.10. That is a margin of safety of -917.6%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
44 out of 100, which we rate "On Watch", on 11 of 12 value investing signals.